In this episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs is joined by Dr. Andrew Satterlee, Dr. Breanna Mann, and Dr. Shawn Hingtgen to break down a groundbreaking shift in how doctors choose cancer treatments for patients.
Their solution, SLICE (Screening Live Cancer Explants), is changing the speed and accuracy with which clinicians can predict which therapies will work—especially for tough-to-treat tumors like glioblastoma. Discover why traditional genomic testing doesn’t always provide the answers patients need, and how SLICE delivers drug response results using live patient tumor tissue within just four days. The team explains the science, shares real-world findings, and discusses how functional assays like SLICE aim to improve outcomes, cut down the trial-and-error, and could soon guide clinical practice and CAR T cell therapy decisions.
Catch this episode now to see what’s next for making cancer care faster, smarter, and more patient-focused.
Podden och tillhörande omslagsbild på den här sidan tillhör
Labcorp. Innehållet i podden är skapat av Labcorp och inte av,
eller tillsammans med, Poddtoppen.
